A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours

British Journal of Cancer

Volumn 95, Issue 5, 2006, Pages 571-580

  Lowis, S ^a   Lewis, I ^b   Elsworth, A ^c   Weston, C ^c   Doz, F ^d   Vassal, G ^e   Bellott, R ^f   Robert, J ^f   Pein, F ^e   Ablett, S ^c   Pinkerton, R ^g   Frappaz, D ^h  

^a Royal Hospital for Children   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d INSTITUT CURIE   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f INSTITUT BERGONIÉ   (France)

^g Royal Marsden Hospital   (United Kingdom)

^h CENTRE LÉON BÉRARD   (France)

Author keywords

Anthracycline; Cardiotoxicity; Childhood cancer; Children; DaunoXome; Phase I

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; FEMALE; FEVER; FOLLOW UP; HEART FAILURE; HUMAN; INFECTION; LEUKOPENIA; LONG TERM CARE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PAIN; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; ELECTROCARDIOGRAPHY; HEART; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LIPOSOMES; NEOPLASMS; PATIENT SELECTION; RECURRENCE;

EID: 33748286801     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603288     Document Type: Article

References (33)

1. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H (2003) Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82: 218-222
2. Bellott R, Auvrignon A, Leblanc T, Perel Y, Gandemer V, Bertrand Y, Mechinaud F, Bellenger P, Vernois J, Leverger G, Baruchel A, Robert J (2001) Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 47: 15-21
3. Casper ES, Gaynor JJ, Hajdu SI, Magill GB, Tan C, Friedrich C, Brennan MF (1991) A prospective randomized trial of adjuvant chemotherapy with bolus vs continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 68: 1221-1229
4. Cusack BJ, Musser B, Gambliel H, Hadjokas NE, Olson RD (2003) Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats. Cancer Chemother Pharmacol 51: 139-146
5. Cusack BJ, Young SP, Driskell J, Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32: 53-58
6. Doz F, Gentet JC, Pein F, Frappaz D, Chastagner P, Moretti S, Vassal G, Arditti J, Tellingen OV, Iliadis A, Catalin J (2001) Phase I trial and pharmacological study of a 3-h paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer 84: 604-610
7. Eckardt JR, Campbell E, Burris HA, Weiss GR, Rodriguez GI, Fields SM, Thurman AM, Peacock NW, Cobb P, Rothenberg ML (1994) A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol 17: 498-501
8. Forssen EA, Coulter DM, Proffitt RT (1992) Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52: 3255-3261
9. Forssen EA, Ross ME (1994) DaunoXome treatment of solid tumours: preclinical and clinical investigations. J Liposome Res 4: 481
10. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13: 996-1003
11. Guaglianone P, Chan K, DelaFlor-Weiss E, Hanisch R, Jeffers S, Sharma D, Muggia F (1994) Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 12: 103-110
12. Gupta M, Steinherz PG, Cheung NK, Steinherz L (2003) Late cardiotoxicity after bolus vs infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol 40: 343-347
13. Hempel G, Reinhardt D, Creutzig U, Boos J (2003) Population pharmacokinetics of liposomal daunorubicin in children. Br J Clin Pharmacol 56: 370-377
14. Hortobagyi GN, Yap HY, Kau SW, Fraschini G, Ewer MS, Chawla SP, Benjamin RS (1989) A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12: 57-62
15. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM (1994) A comparison of two phase I trial designs. Stat Med 13: 1799-1806
16. Levitt GA, Dorup I, Sorensen K, Sullivan I (2004) Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol 124: 463-468
17. Lippens RJ (1999) Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors. Pediatr Hematol Oncol 16: 131-139
18. McBride NC, Cavenagh JD, Ward MC, Grant I, Schey S, Gray A, Hughes A, Mills MJ, Cervi P, Newland AC, Kelsey SM (2001) Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poorprognosis non-Hodgkins lymphoma. Leuk Lymphoma 42: 89-98
19. Missov E, Calzolari C, Davy JM, Leclercq F, Rossi M, Pau B (1997) Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 8: 537-541
20. Money-Kyrle JF, Bates F, Ready J, Gazzard BG, Phillips RH, Boag FC (1993) Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin Oncol (R Coll Radiol) 5: 367-371
21. Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, Villain E, De Vathaire F, Sidi D, Hartmann O (2004) Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 91: 37-44
22. Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkio M (2003) Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 21: 2349-2356
23. Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J, Presant J (1993) Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 341: 1242-1243
24. Richardson DS, Kelsey SM, Johnson SA, Tighe M, Cavenagh JD, Newland AC (1997) Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs 15: 247-253
25. Sparano JA, Brown DL, Wolff AC (2002) Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Safety 25: 301-311
26. Speyer JL, Green MD, Dubin N, Blum RH, Wernz JC, Roses D, Sanger J, Muggia FM (1985) Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med 78: 555-563
27. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4-20 years after completing anthracycline therapy. JAMA 266: 1672-1677
28. van Dalen EC, Caron HN, Dickinson HO, Kremer LCM (2005) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, Issue 1. Art. No.: CD003917. DOI: 10.1002/14651858.CD003917.pub2
29. Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, O'Quigley J, Germa C, Risse ML, Mignard D, Pein F (2003) A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21: 3844-3852
30. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717
31. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM (1977) Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 62: 200-208
32. Weiss AJ, Manthel RW (1977) Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer 40: 2046-2052
33. Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, Weiss GR, Ryan J, Benjamin RS, Baker LH (1991) Phase III comparison of doxorubicin and dacarbazine given by bolus vs infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 83: 926-932